Selegiline transdermal system: a novel treatment option for major depressive disorder

Bibliography

• Robinson DS. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull 2002;36:124-38
   PubMedGoogle Scholar
• Ban TA. Pharmacotherapy of depression: a historical analysis. J Neural Transm 2001;108:707-16
   PubMed Web of Science ®Google Scholar
• Kline NS. Clinical experience with iproniazid (Marsilid). J Clin Exp Psychopathol 1958;19:72-8
   PubMedGoogle Scholar
• Lopez-Munoz F, Alamo C, Juckel G, Assion H. Half a century of antidepressant drugs. on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. Guest editorial. J Clin Psychopharmacol 2007;27:555-9
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Chopra M. Monoamine oxidase inhibitors revisited. Psychiatr Ann 2001;31:361-70
   Web of Science ®Google Scholar
• Blackwell B. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet 1963;2:849-51
   PubMed Web of Science ®Google Scholar
• Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr 2004;9:808-16, 818-821
   PubMed Web of Science ®Google Scholar
• Greden JF. Unmet need: what justifies the search for a new antidepressant? J Clin Psychiatry 2006;63(Suppl 2):3-7
   Google Scholar
• Billett EE. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicol 2004;25:139-48
   PubMed Web of Science ®Google Scholar
• Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicol 2004;25:215-21
   PubMed Web of Science ®Google Scholar
• Saura Marti J, Kettler R, Da Prada M, Richards JG et al. Molecular neuroanatomy of MAO-A and MAO-B. J Neural Transm Suppl 1990;32:49-53
   PubMedGoogle Scholar
• EMSAM [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. Feb 2006
   Google Scholar
• Patkar AA, Pae C, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr 2006;11:363-75
   PubMed Web of Science ®Google Scholar
• Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacol 1999;20:226-47
   PubMed Web of Science ®Google Scholar
• Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-97
   PubMed Web of Science ®Google Scholar
• Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 1986;46:1359-65
   PubMed Web of Science ®Google Scholar
• Glover V, Elsworth JD, Sandler M. Dopamine oxidation and its inhibition by l-deprenyl in man. J Neural Transm Suppl 1980;16:163-72
   Google Scholar
• Barrett JS, Hochadel TJ, Morales RJ, et al. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. Am J Ther 1996;3:688-98
   PubMedGoogle Scholar
• Rohatagi S, Barrett JS, DeWitt KE, Morales RJ. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm Drug Dispos 1997;18:567-84
   PubMed Web of Science ®Google Scholar
• Wecker L, James S, Copeland N, Pacheco MA. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry 2003;54:1099-104
   PubMed Web of Science ®Google Scholar
• Oldfield V, Keating GM, Perry CM. Rasagiline: a review of its use in the management of Parkinson's disease. Drugs 2007;67:1725-47
   PubMed Web of Science ®Google Scholar
• Chen DT, Ruch R. Safety of moclobemide in clinical use. Clin Neuropharmacol 1993;16(Suppl 2):S63-8
   Google Scholar
• Youdim MB. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr Scand Suppl 1995;386:5-7
   PubMedGoogle Scholar
• Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11
   PubMed Web of Science ®Google Scholar
• Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 2003;55:27-34
   PubMed Web of Science ®Google Scholar
• Rohatagi S, Barrett JS, McDonald LJ, et al. Selegiline percutaneous absorption in various species and metabolism by human skin. Pharm Res 1997;14:50-5
   PubMed Web of Science ®Google Scholar
• Blob LF, Sharoky M. Safety and efficacy of the selegiline transdermal system for ADHD. 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Oct 2002
   Google Scholar
• Wagner GC, Walsh SL. Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage. Int J Dev Neurosci 1991;9:171-4
   PubMed Web of Science ®Google Scholar
• Cadet JL, Sheng P, Ali S, et al. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem 1994;62:380-3
   PubMed Web of Science ®Google Scholar
• Abassi ZA, Binah O, Youdim MBH. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Brit J Pharmacol 2004;143:371-8
   PubMed Web of Science ®Google Scholar
• Azzaro AJ, Ziemniak J, Kemper E, et al. Selegiline transdermal system: an examination of the potencial for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. J Clin Pharmacol 2007;47:146-58
   PubMed Web of Science ®Google Scholar
• Krishnan R. Advances in psychopharmacology: MAOIs. Scientific report session. Abstract presented at the 157th Annual Meeting of the American Psychiatric Association. May 2004
   Google Scholar
• Semla TP, Beizer JL, Higbee MD. Geriatric dosage handbook, 12th edition., Lexi-Comp, Inc., Hudson, OH. 2007
   Google Scholar
• Gordon MN, Muller CD, Sherman KA, et al. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol Biochem Behav 1999;63:501-6
   PubMed Web of Science ®Google Scholar
• Barrett JS, Hochadel TJ, Morales RJ, et al. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. J Clin Pharmacol 1997;37:238-47
   PubMed Web of Science ®Google Scholar
• Berlin I, Zimmer R, Cournot A, et al. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther 1989;46:344-51
   PubMed Web of Science ®Google Scholar
• Simpson GM, Gratz SS. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers. Clin Pharmacol Ther 1992;52:286-91
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002;159:1869-75
   PubMed Web of Science ®Google Scholar
• Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003;64:208-14
   PubMed Web of Science ®Google Scholar
• Feiger AD, Rickels K, Rynn MA, et al. Selegiline trandermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 2006;67:1354-61
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006;26:579-86
   PubMed Web of Science ®Google Scholar
• Robinson DS, Gilmor ML, Yang Y, et al. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacol Bull 2007;40:15-28
   PubMedGoogle Scholar
• Robinson DS, Amsterdam JD. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J Affect Disord 2008;105:15-23
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Eisfeld BS, Dickens SE, et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline and venlafaxine. J Clin Psychiatry 2000;61:276-81
   PubMed Web of Science ®Google Scholar
• Nandagopal JJ, Hochadel TJ, Kemper E, et al. A phase IV, double-blind, placebo-controlled, flexible-dose study of selegiline transdermal system (EMSAM) for the treatment of adolescents with major depression: an interim safety report. 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Oct 2008
   Google Scholar
• Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Alpert JE, Pava J, et al. Course and treatment of atypical depression. J Clin Psychiatry 1998;59(Suppl 18):5-9
   PubMed Web of Science ®Google Scholar
• Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry 1995;152:31-6
   PubMed Web of Science ®Google Scholar
• Henkel V, Mergl R, Allgaier AK, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res 2006;141:89-101
   PubMed Web of Science ®Google Scholar
• Janicak PG, Pandey GN, Davis JM, et al. Response of psychotic and nonpsychotic depression to phenelzine. Am J Psychiatry 1988;1451:93-5
   Google Scholar
• Davidson JR, McLeod MN, Kurland AA, et al. Antidepressant drug therapy in psychotic depression. Br J Psychiatry 1977;131:493-6
   PubMed Web of Science ®Google Scholar
• Vallejo J, Gasto C, Catalan R, et al. Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry 1987;151:639-42
   PubMed Web of Science ®Google Scholar
• Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195-8
   PubMed Web of Science ®Google Scholar
• Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910-6
   PubMed Web of Science ®Google Scholar
• Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
   PubMed Web of Science ®Google Scholar
• McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163:1531-41
   PubMed Web of Science ®Google Scholar
• Nolen WA, Van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988;78:676-83
   PubMed Web of Science ®Google Scholar
• Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 2000;14:3-20
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression–a retrospective study. J Affect Disord 2005;89:183-8
   PubMed Web of Science ®Google Scholar
• McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;150:118-23
   PubMed Web of Science ®Google Scholar
• Mechcatie E. Transdermal MAO inhibitor patch effective for ADHD. Clin Psychiatry News 2003;31:18
   Google Scholar
• Houtsmuller EJ, Notes LD, Newton T, et al. Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (Berl) 2004;172:31-40
   PubMed Web of Science ®Google Scholar
• Sacktor N, Schifitto G, McDermott MP, et al. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000;54:233-5
   PubMed Web of Science ®Google Scholar
• Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007;69:1314-21
   PubMed Web of Science ®Google Scholar
• Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 2003;98:1403-7
   PubMed Web of Science ®Google Scholar
• George TP, Vessicchio JC, Termine A, et al. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003;53:136-43
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Cohen BM, Salomon MS, et al. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis 1996;184:295-301
   PubMed Web of Science ®Google Scholar
• Gupta S, Droney T, Kyser A, Keller P. Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Compr Psychiatry 1999;40:148-50
   PubMed Web of Science ®Google Scholar
• Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current pychiatric practice. J Psychiatr Pract 2004;10:239-48
   PubMedGoogle Scholar
• Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 1997;48:1070-7
   PubMed Web of Science ®Google Scholar
• Azzaro AJ, Blob LF, Kemper EM, et al. Pressor effects of oral tyramine and over-the-counter (OTC) sympathomimetic amines following steady-state transdermal administration of selegiline to healthy volunteers [abstract 268]. In: Scientific Abstracts of the 2000 Annual Meeting of the American College of Neuropsychopharmacology
   Google Scholar
• Blob LF, Vandenberg CM, Kemper EM, et al. Safety of selegiline transdermal system: concomitant administration of pseudoephedrine, a sympathomimetic amine. Abstract presented at Annual Meeting of the New Clinical Drug Evaluation Unit. May 2001
   Google Scholar